News

Myelin is an insulating material that allows proper function of neurons. It made of specialised cells of the nervous system called oligodendrocytes. This myelin sheath offers a protective

The inhaled mRNA-based therapeutic is intended for people with CF, including those with genotypes that are not responsive to approved CFTR modulators. ReCode Therapeutics CEO Shehnaaz Suliman said:

The FDA is expected to complete the NDA review in October this year and stated that it currently has no plans to hold an advisory committee meeting to

Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody to treat adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) following two or more lines of

As per the terms of the agreement, Spruce will get an upfront payment of $15m from Kaken. It will also be eligible to get further payments following the

BTD for IBI351 (GFH925) has been granted to treat advanced non-small cell lung cancer (NSCLC) patients with KRASG12C mutation who have undergone at least one prior line of

Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody. It targets both GPRC5D, a novel drug target that is on some normal cells but overexpressed

Cilta-cel is a BCMA-directed and genetically modified autologous T-cell immunotherapy that involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR), which detects

The regulatory acceptance of application for marketing authorisation of tislelizumab is to treat first-line unresectable or metastatic HCC patients. The humanised IgG4 anti-PD-1 monoclonal antibody tislelizumab has been